References
Acanfora, D., Ciccone, M.M., Scicchitano, P., Acanfora, C., Casucci, G (2020). Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother.,6(3),135-136. Gallagher, P.E., Ferrario, C.M., Tallant, E.A (2008). Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol., 295(6), H2373-9. Iaccarino, G., Grassi, G., Borghi, C., Ferri, C., Salvetti, M., Volpe, M.; SARS-RAS Investigators (2020). Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension, 76(2),366-372. Ibrahim, N.E., McCarthy, C.P., Shrestha, S., Gaggin, H.K., Mukai, R., Szymonifka, J., … Januzzi, J.L. Jr (2019). Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol.,73(11),1273-1284. Volpe, M., Rubattu, S., Burnett, J. Jr (2014). Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J.,35(7), 419-25.